较高抗TNF-α药物水平与克罗恩病肛周瘘影像学结局改善相关
本横断面回顾性多中心研究纳入193例维持英夫利西单抗或阿达木单抗治疗的肛周瘘型克罗恩病患者,评估抗TNF药物水平与MRI影像学结局的关联。结果显示,影像学愈合者药物水平中位数更高,且随药物水平三分位升高炎症评分子分呈递增性降低。
要点
- 影像学愈合者英夫利西单抗和a阿达木单抗药物水平中位数均高于活动性疾病者
- 随抗TNF药物水平三分位升高,MRI炎症分呈递增性降低
- 较高抗TNF药物水平与肛周瘘影像学愈合和缓解相关
核心结论
- 较高抗TNF药物水平与肛周瘘型克罗恩病MRI影像学结局改善相关,英夫利西单抗和阿达木单抗均随药物水平三分位升高呈递增性改善。
研究设计与样本
- 横断面回顾性多中心研究,纳入193例维持英夫利西单抗(n=117)或阿达木单抗(n=76)治疗的肛周瘘型克罗恩病患者,药物水平检测距肛周MRI在6个月内。
- 排除药物水平与影像学之间调整剂量或接受瘘管手术的患者,采用Van Assche指数评分影像学疾病活动度。
主要发现
- 影像学愈合者英夫利西单抗药物水平中位数6.0 vs 3.9 μg/mL,阿达木单抗9.1 vs 6.2 μg/mL,均P < .05。
- 影像学缓解者英夫利西单抗7.4 vs 3.9 μg/mL(P < .05),阿达木单抗9.8 vs 6.2 μg/mL(P = .07)。
- 随抗TNF药物水平三分位升高,中位炎症评分子分呈显著递增性降低。
关键数值与推荐
- 主要终点影像学愈合定义为炎症评分子分≤6分。
- 次要终点影像学缓解定义为炎症评分子分=0分。
- 炎症评分子分基于T2加权成像高信号、直径>3 mm的集合和直肠壁受累计算。
临床怎么用
- 对肛周瘘型克罗恩病维持治疗患者,可考虑监测抗TNF药物水平以指导影像学结局优化。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Higher anti-tumor necrosis factor-α (TNF) drug levels are associated with improved clinical healing of Crohn's perianal fistulas. It is unclear whether this leads to improved healing on radiologic assessment. We aimed to evaluate the association between anti-TNF drug levels and radiologic outcomes in perianal fistulising Crohn's disease. METHODS: A cross-sectional retrospective multicenter study was undertaken. Patients with perianal fistulising Crohn's disease on maintenance infliximab or adalimumab, with drug levels within 6 months of perianal magnetic resonance imaging were included. Patients receiving dose changes or fistula surgery between drug level and imaging were excluded. Radiologic disease activity was scored using the Van Assche Index, with an inflammatory subscore calculated using indices: T2-weighted imaging hyperintensity, collections >3 mm diameter, rectal wall involvement. Primary endpoint was radiologic healing (inflammatory subscore ≤6). Secondary endpoint was radiologic remission (inflammatory subscore = 0). RESULTS: Of 193 patients (infliximab, n = 117; adalimumab, n = 76), patients with radiologic healing had higher median drug levels compared with those with active disease (infliximab 6.0 vs 3.9 μg/mL; adalimumab 9.1 vs 6.2 μg/mL; both P < .05). Patients with radiologic remission also had higher median drug levels compared with those with active disease (infliximab 7.4 vs 3.9 μg/mL; P < .05; adalimumab 9.8 vs 6.2 μg/mL; P = .07). There was a significant incremental reduction in median inflammatory subscores with higher anti-TNF drug level tertiles. CONCLUSIONS: Higher anti-TNF drug levels were associated with improved radiologic outcomes on magnetic resonance imaging in perianal fistulising Crohn's disease, with an incremental improvement at higher drug level tertiles for both infliximab and adalimumab.
引用
- De Gregorio M, Lee T, Krishnaprasad K, et al. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. Clin Gastroenterol Hepatol. 2021. PMID: 34389484. doi:10.1016/j.cgh.2021.07.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。